oral solution

DRUG3 trials

Sponsors

Mirum Pharmaceuticals Inc., Ferraz Lynce Especialidades Farmaceuticas S.A., Centre for Addiction and Mental Health

Conditions

Alcohol Use DisorderCholestatic PruritusChronic neuropathic pain due to multiple sclerosis (MS)

Phase 2

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Active, not recruitingNCT06512389

Centre for Addiction and Mental HealthAlcohol Use Disorder

Start: 2024-08-16End: 2026-09-30Target: 36Updated: 2026-09-16

A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain

RecruitingCTIS2024-520287-34-01

Ferraz Lynce Especialidades Farmaceuticas S.A.Chronic neuropathic pain due to multiple sclerosis (MS)

Start: 2025-09-12Target: 68Updated: 2026-01-13

Phase 3

Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus

RecruitingCTIS2024-511287-85-00

Mirum Pharmaceuticals Inc.Cholestatic Pruritus

Start: 2025-02-17Target: 37Updated: 2025-10-24